Between Dec. 23, 2024 and Jan. 3, 2025, eCommons staff will not be available to answer email and will not be able to provide DOIs until after Jan. 6. If you need a DOI for a dataset during this period, consider Dryad or OpenICPSR. If you need support submitting material before the winter break, please contact us by Thursday, Dec. 19 at noon. Thank you!

eCommons

 

Treating Glaucoma with Porous Contact Lens

Other Titles

Abstract

Glaucoma is a family of diseases that afflicts 65 million people worldwide. Primary open angle glaucoma is the most common type of glaucoma. This is characterized by increased intraocular pressure (IOP) within the eye that results in vision loss. Current therapeutic drugs include Timolol and Brimonidine which studies have shown to yield a greater decrease in IOP through combined drug therapy than monotherapy. In 2007 Combigan, an eye drop that combines the therapeutic effects of Timolol and Brimonidine, was approved for use by the FDA. This project proposes a method for treating glaucoma through delivery of Combigan via a contact lens through which the drugs will diffuse into the eye over a period of time. We modeled the diffusion of two drugs, Timolol and Brimonidine, through four layers of the human eye. The drug was delivered via a contact lens, so that the concentration of drug in the aqueous humor would remain above the minimum effective dosage for longer than if it were delivered via eye drops. We calculated the concentration of each drug in all layers of the eye for 12 hours. Our model was verified by experimental data in the published literature. Our model failed to deliver solely Timolol or Brimonidine for 12 hours, which was our goal, but still was significantly more effective than eye drops. However, throughout the twelve hours there was at least one drug in the aqueous humor and since both drugs lower IOP through different mechanisms our model did deliver treat the glaucoma for the whole twelve hours. If it were possible to lower the diffusivity of Timolol through the stroma, this would allow for Timolol to remain longer in the aqueous humor thus making the contacts better at treating glaucoma.
A sensitivity analysis demonstrated that our model was robust in the tear film and relatively robust in the contact lens. However, the model was particularly sensitive to diffusivity in the stroma layer, as the stroma acts as the final barrier to aqueous humoral penetration and is quite thick. Brimonidine was delivered at a more constant rate, but at a lower concentration than Timolol. It also took six times longer than Timolol to reach its maximum concentration in the aqueous humor. Drug delivery via contact lenses is a feasible technology as more effective than eye drops, but can be improved by designing a time-release drug that diffuses more slowly. Further research needs to be conducted in order to investigate the practicality of this method.

Journal / Series

BEE 453

Volume & Issue

Description

Sponsorship

Date Issued

2008-07-23T19:58:40Z

Publisher

Keywords

Glaucoma; drug delivery; contact lens

Location

Effective Date

Expiration Date

Sector

Employer

Union

Union Local

NAICS

Number of Workers

Committee Chair

Committee Co-Chair

Committee Member

Degree Discipline

Degree Name

Degree Level

Related Version

Related DOI

Related To

Related Part

Based on Related Item

Has Other Format(s)

Part of Related Item

Related To

Related Publication(s)

Link(s) to Related Publication(s)

References

Link(s) to Reference(s)

Previously Published As

Government Document

ISBN

ISMN

ISSN

Other Identifiers

Rights

Rights URI

Types

presentation

Accessibility Feature

Accessibility Hazard

Accessibility Summary

Link(s) to Catalog Record